Dennis J. Pavón-Varela
Dennis J. Pavón-Varela has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- César Alas-Pineda
Quantitative Biomedical Sciences Doctoral Program, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
5 shared publications - Gustavo Ferrer
Department of Pulmonary and Critical Care Medicine, Aventura Hospital and Medical Center, Aventura, FL 33180, USA
5 shared publications - Kristhel Gaitán-Zambrano
Facultad de Medicina y Cirugía, Universidad Católica de Honduras - Campus San Pedro y San Pablo, San Pedro Sula, Cortés, Honduras
5 shared publications - Carlos Coto-Tejeda
Department of Research and Development, Moxie Health Group, Hallandale Beach, FL 33009, USA
3 shared publications - Jhacely Medina-Mejía
Department of Research and Development, Moxie Health Group, Hallandale Beach, FL 33009, USA
3 shared publications Agustin Yppolito
Department of Pulmonary Research, Ferrer Pulmonary Institute, Miami, Florida, USA
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3598
Pregnancy-Recognized Obstructive Sleep Apnea and Maternal–Fetal Outcomes: A Narrative Review of Gestational Rhinitis, Upper-Airway Mechanisms, and Treatment Evidence
Background/Objectives: Pregnancy-recognized obstructive sleep apnea (POSA) is an operational construct, not a validated biological phenotype, and remains underrecognized in prenatal care. This review synthesizes evidence on POSA-related outcomes, evaluates gestational rhinitis as a candidate contributor to upper-airway vulnerability, and distinguishes pregnancy safety from demonstrated efficacy for OSA-related endpoints. Methods: This structured narrative review, informed by SANRA criteria, used a structured PubMed search (7 March 2026) with targeted supplementary searches through 9 October 2026, across six predefined domains. Results: Pregnancy-recognized OSA is associated in observational studies with hypertensive disorders, preterm birth, impaired fetal growth (in small pregnancy-specific studies), and severe maternal morbidity; residual confounding by obesity precludes causal inference. In a 2024 meta-analysis of randomized and observational studies (n = 809), continuous positive airway pressure (CPAP) was associated with lower risks of gestational hypertension (RR, 0.65; 95% CI, 0.47–0.89) and preeclampsia (RR, 0.70; 95% CI, 0.50–0.98). Although secondary endpoints in individual trials suggested benefit, the pooled preeclampsia effect was fragile in sensitivity and subgroup analyses. Gestational rhinitis affects approximately one in five pregnant women and is a plausible but untested contributor to pregnancy-recognized OSA. Saline irrigation, budesonide (mainly inhaled-exposure data), and chlorpheniramine have gestational safety data, but the only randomized trial of an intranasal corticosteroid in gestational rhinitis was null, and we identified no study of OSA endpoints. Conclusions: Given the largely observational evidence, objective testing and individualized treatment may be considered in high-risk patients, pending adequately powered trials. CPAP is the standard treatment for objectively confirmed OSA.
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3598
Open AccessPregnancy-Recognized Obstructive Sleep Apnea and Maternal–Fetal Outcomes: A Narrative Review of Gestational Rhinitis, Upper-Airway Mechanisms, and Treatment Evidence
Background/Objectives: Pregnancy-recognized obstructive sleep apnea (POSA) is an operational construct, not a validated biological phenotype, and remains underrecognized in prenatal care. This review synthesizes evidence on POSA-related outcomes, evaluates gestational rhinitis as a candidate contributor to upper-airway vulnerability, and distinguishes pregnancy safety from demonstrated efficacy for OSA-related endpoints. Methods: This structured narrative review, informed by SANRA criteria, used a structured PubMed search (7 March 2026) with targeted supplementary searches through 9 October 2026, across six predefined domains. Results: Pregnancy-recognized OSA is associated in observational studies with hypertensive disorders, preterm birth, impaired fetal growth (in small pregnancy-specific studies), and severe maternal morbidity; residual confounding by obesity precludes causal inference. In a 2024 meta-analysis of randomized and observational studies (n = 809), continuous positive airway pressure (CPAP) was associated with lower risks of gestational hypertension (RR, 0.65; 95% CI, 0.47–0.89) and preeclampsia (RR, 0.70; 95% CI, 0.50–0.98). Although secondary endpoints in individual trials suggested benefit, the pooled preeclampsia effect was fragile in sensitivity and subgroup analyses. Gestational rhinitis affects approximately one in five pregnant women and is a plausible but untested contributor to pregnancy-recognized OSA. Saline irrigation, budesonide (mainly inhaled-exposure data), and chlorpheniramine have gestational safety data, but the only randomized trial of an intranasal corticosteroid in gestational rhinitis was null, and we identified no study of OSA endpoints. Conclusions: Given the largely observational evidence, objective testing and individualized treatment may be considered in high-risk patients, pending adequately powered trials. CPAP is the standard treatment for objectively confirmed OSA.
- Open Access
- 8 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1128
Human Factors and Device Engineering in OTC Intranasal Drug Delivery: GentleMist Technology™
Intranasal drug delivery is noninvasive, rapid-acting, and well suited to self-administration, yet the real-world performance of nasal sprays depends on the interaction among formulation, device mechanics, nasal anatomy, and user technique rather than on the active ingredient alone. This narrative review examines how aerosol science, regional targeting, and human factors jointly shape intranasal performance, using GentleMist Technology™ as a representative example of emerging device-centered development. Computational fluid dynamics (CFD) and anatomically informed in vitro models indicate that device geometry, plume characteristics, and administration angle can significantly alter where a dose is deposited, while human factors research identifies priming, positioning, and angulation as key determinants of successful over-the-counter (OTC) use. We summarize early feasibility data suggesting that angle-optimized administration may increase posterior nasopharyngeal delivery and that essential tasks are feasible for lay users, with priming emerging as a specific usability vulnerability. We also review preliminary clinical evidence on a chlorpheniramine maleate (CPM)-based intranasal formulation in allergic rhinitis and viral upper respiratory illness. Although the strongest device-specific findings remain preliminary and require independent replication, they support an emerging shift from a formulation-centered model toward an integrated device–formulation–user paradigm.
- 8 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1128
Open AccessHuman Factors and Device Engineering in OTC Intranasal Drug Delivery: GentleMist Technology™
Intranasal drug delivery is noninvasive, rapid-acting, and well suited to self-administration, yet the real-world performance of nasal sprays depends on the interaction among formulation, device mechanics, nasal anatomy, and user technique rather than on the active ingredient alone. This narrative review examines how aerosol science, regional targeting, and human factors jointly shape intranasal performance, using GentleMist Technology™ as a representative example of emerging device-centered development. Computational fluid dynamics (CFD) and anatomically informed in vitro models indicate that device geometry, plume characteristics, and administration angle can significantly alter where a dose is deposited, while human factors research identifies priming, positioning, and angulation as key determinants of successful over-the-counter (OTC) use. We summarize early feasibility data suggesting that angle-optimized administration may increase posterior nasopharyngeal delivery and that essential tasks are feasible for lay users, with priming emerging as a specific usability vulnerability. We also review preliminary clinical evidence on a chlorpheniramine maleate (CPM)-based intranasal formulation in allergic rhinitis and viral upper respiratory illness. Although the strongest device-specific findings remain preliminary and require independent replication, they support an emerging shift from a formulation-centered model toward an integrated device–formulation–user paradigm.
- Open Access
- 19 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 796
New Technique for Tramadol Dose Accuracy: Are Dosing Pumps the Solution?
Background/Objectives: Chronic pain represents a core global health burden and remains a leading cause of disability and reduced quality of life. Tramadol is a widely prescribed analgesic with a dual-opioid and non-opioid mechanism of action; however, safety concerns persist. This scoping review summarizes current evidence on tramadol pharmacology, dosing, and safety. Methods: A systematic literature search was conducted across main scientific databases to identify preclinical and clinical studies evaluating tramadol pharmacokinetics, safety, and dosing. Results: The same tramadol presentations have been used for several years, with a high overdose risk due to incorrect dosing measurements. Dosing pump devices represent a viable solution to improve dosing accuracy and minimize this risk. Conclusions: Tramadol drops seem like an easier administration pathway but require careful handling when taking the prescribed dose. A dosing pump in the medication bottle will improve dosing accuracy.
- 19 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 796
Open AccessNew Technique for Tramadol Dose Accuracy: Are Dosing Pumps the Solution?
Background/Objectives: Chronic pain represents a core global health burden and remains a leading cause of disability and reduced quality of life. Tramadol is a widely prescribed analgesic with a dual-opioid and non-opioid mechanism of action; however, safety concerns persist. This scoping review summarizes current evidence on tramadol pharmacology, dosing, and safety. Methods: A systematic literature search was conducted across main scientific databases to identify preclinical and clinical studies evaluating tramadol pharmacokinetics, safety, and dosing. Results: The same tramadol presentations have been used for several years, with a high overdose risk due to incorrect dosing measurements. Dosing pump devices represent a viable solution to improve dosing accuracy and minimize this risk. Conclusions: Tramadol drops seem like an easier administration pathway but require careful handling when taking the prescribed dose. A dosing pump in the medication bottle will improve dosing accuracy.
- Open Access
- 25 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 670
Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment
Background: H1-antihistamines are widely used for allergic and upper respiratory conditions; however, several agents included in this class have been associated with cardiac electrophysiological adverse effects, including QT interval prolongation and torsades de pointes (TdP). These effects are largely exposure-dependent and mechanistically linked to inhibition of cardiac ion channels. Chlorpheniramine maleate (CPM), a first-generation H1-antihistamine, has been implicated in arrhythmic events primarily under conditions of increased systemic exposure, prompting interest in whether alternative routes of administration may lower cardiac risk. Methods: This narrative review integrates mechanistic, preclinical, clinical, pharmacokinetic, and regulatory evidence. Information was extracted from PubMed, Google Scholar, and Scielo using search terms such as cardiotoxicity, chlorpheniramine, QT prolongation, intranasal administration, and cardiac arrhythmias, with no language restriction. Results: Comparative pharmacokinetic evidence shows that, on a dose-normalized basis, intranasal and oral chlorpheniramine exhibit comparable bioavailability; however, in a clinical context, intranasal doses (1.12–2.24 mg) are lower than oral daily doses (4–12 mg/day), resulting in a lower systemic exposure (Cmax and AUC) with intranasal administration. Available pharmacovigilance or epidemiological data have not specifically evaluated intranasal chlorpheniramine, and the number of dedicated safety trials remains limited. Conclusions: Preclinical, in vitro, mechanistic studies suggest that intranasal administration of chlorpheniramine should confer superior cardiac safety compared to the oral route. However, clinical data from human studies directly comparing the cardiac safety of intranasal chlorpheniramine versus systemic chlorpheniramine is extremely limited. More data from clinical trials, case–control studies, and regulatory databases are needed to validate these theoretical claims.
- 25 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 670
Open AccessCardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment
Background: H1-antihistamines are widely used for allergic and upper respiratory conditions; however, several agents included in this class have been associated with cardiac electrophysiological adverse effects, including QT interval prolongation and torsades de pointes (TdP). These effects are largely exposure-dependent and mechanistically linked to inhibition of cardiac ion channels. Chlorpheniramine maleate (CPM), a first-generation H1-antihistamine, has been implicated in arrhythmic events primarily under conditions of increased systemic exposure, prompting interest in whether alternative routes of administration may lower cardiac risk. Methods: This narrative review integrates mechanistic, preclinical, clinical, pharmacokinetic, and regulatory evidence. Information was extracted from PubMed, Google Scholar, and Scielo using search terms such as cardiotoxicity, chlorpheniramine, QT prolongation, intranasal administration, and cardiac arrhythmias, with no language restriction. Results: Comparative pharmacokinetic evidence shows that, on a dose-normalized basis, intranasal and oral chlorpheniramine exhibit comparable bioavailability; however, in a clinical context, intranasal doses (1.12–2.24 mg) are lower than oral daily doses (4–12 mg/day), resulting in a lower systemic exposure (Cmax and AUC) with intranasal administration. Available pharmacovigilance or epidemiological data have not specifically evaluated intranasal chlorpheniramine, and the number of dedicated safety trials remains limited. Conclusions: Preclinical, in vitro, mechanistic studies suggest that intranasal administration of chlorpheniramine should confer superior cardiac safety compared to the oral route. However, clinical data from human studies directly comparing the cardiac safety of intranasal chlorpheniramine versus systemic chlorpheniramine is extremely limited. More data from clinical trials, case–control studies, and regulatory databases are needed to validate these theoretical claims.
- Open Access
- 1 October 2025
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 20 (Vol. 20 (2) , 1050
Implementing oxygen saturation-based criteria for discontinuation of long-term oxygen therapy in nursing home residents with chronic respiratory disease
Background: Chronic respiratory diseases represent a significant global health burden, affecting millions of individuals. Long-term oxygen therapy (LTOT) has been a key treatment for patients with chronic hypoxemia due to these conditions, demonstrating benefits for survival and quality of life. Methods: An observational, analytical, retrospective cohort study was conducted to evaluate clinical indicators for safely discontinuing oxygen therapy in 36 patients aged 50 years or older with chronic respiratory diseases residing in five nursing homes. Data included sociodemographic and clinical variables, such as comorbidities, oxygen saturation levels, and treatment details. A cohort of 36 nursing home residents with chronic respiratory diseases was analyzed. Results: The study revealed that 83.3% of patients had at least one comorbidity. Most patients (80.6%) used a nasal cannula for oxygen delivery, with a mean flow rate of 2.06 L/min. Approximately 80.6% achieved oxygen saturation >92% without supplemental oxygen. None of the patients who discontinued oxygen required readmission or oxygen reinstatement within the 4-week follow-up period. Conclusions: This study provides preliminary evidence that achieving oxygen saturation >92% at rest or in exertion may represent a potential clinical indicator for safely discontinuing supplemental oxygen in patients with chronic respiratory diseases. However, given the retrospective design and small sample size, these findings should be interpreted cautiously and validated in larger, prospective studies.
- 1 October 2025
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 20 (Vol. 20 (2) , 1050
Open AccessImplementing oxygen saturation-based criteria for discontinuation of long-term oxygen therapy in nursing home residents with chronic respiratory disease
Background: Chronic respiratory diseases represent a significant global health burden, affecting millions of individuals. Long-term oxygen therapy (LTOT) has been a key treatment for patients with chronic hypoxemia due to these conditions, demonstrating benefits for survival and quality of life. Methods: An observational, analytical, retrospective cohort study was conducted to evaluate clinical indicators for safely discontinuing oxygen therapy in 36 patients aged 50 years or older with chronic respiratory diseases residing in five nursing homes. Data included sociodemographic and clinical variables, such as comorbidities, oxygen saturation levels, and treatment details. A cohort of 36 nursing home residents with chronic respiratory diseases was analyzed. Results: The study revealed that 83.3% of patients had at least one comorbidity. Most patients (80.6%) used a nasal cannula for oxygen delivery, with a mean flow rate of 2.06 L/min. Approximately 80.6% achieved oxygen saturation >92% without supplemental oxygen. None of the patients who discontinued oxygen required readmission or oxygen reinstatement within the 4-week follow-up period. Conclusions: This study provides preliminary evidence that achieving oxygen saturation >92% at rest or in exertion may represent a potential clinical indicator for safely discontinuing supplemental oxygen in patients with chronic respiratory diseases. However, given the retrospective design and small sample size, these findings should be interpreted cautiously and validated in larger, prospective studies.